On Dec. 12th of 2010, Fosun Pharma announced that it would cooperate with Shenyang Hongqi Pharmaceutical Co., Ltd., the leading enterprise of antitubercular drugs industry in China, to promote the internationalization of China’s antitubercular drugs. On the same day, the two parties held a signing ceremony when Fosun Pharma transferred its 70% shares to Hongqi Pharma. Under this cooperation, antitubercular drugs will be the second stepping-stone, following artesunate, for Fosun Pharma to enter into the global pharmaceutical market.

China is one of 22 countries worldwide which are under high burden of tuberculosis. Currently, around our nation there are about 550 million people are infected with tuberculosis, and the infection rate is as much as 44.5% which is higher than the global average rate by 1/3, the patients number ranks the second in the world. It is reported by WHO, the tuberculosis has the trend to be more serious all around the world.

Shenyang Hongqi Pharmaceutical Co., Ltd. is a leading enterprise of antitubercular drugs industry in China. It is the only manufacturer and drafter of related quality standards for three listed and self-developed first class 550 antitubercular new drugs (Ethambutol Hydrochloride Pyrazinamide Rifampicin and Isoniazid Tablets; Ethambutol Hydrochloride, Rifampicin and Isoniazid Tablets; Rifampicin and Isoniazid Tablets) while it owns the independent inteleectual property rights of these drugs; It is also only manufacturer in China for four components in line with WHO recommended specifications (Ethambutol Hydrochloride Pyrazinamide Rifampicin and Isoniazid Tablets II). It had won continually in many great bidding projects, listing as the TB Control Project that the Japanese government aided to poor western areas in China, the anti-TB Drugs and Facilities Project by our central government, the TB Control Project loaned by Bank of World and donated by the British Government. Also it has already become the key manufacturer of antitubercular drugs recommended globally by WHO, the appointed manufacturer of drugs for “TB Control Project” by Chinese Ministry of Health while it is also the largest provider for antitubercular development and production base.

Mr. Kang Shusen, the President of Shenyang Hongqi Pharma, sated that, “To take good advantage of Fosun Pharma’s experiences that its anti-malarial medicine - artesunate has passed WHO and PQ certifications and entered into the global market, also to speed up the first class, second class of antitubercular drugs of Hongqi Pharma to pass WHO-GMP and PQ certifications to make them to enter into the global market soon, Hongqi Pharma and Fosun Pharma have made this decision of strategic cooperation.” Shanghai Fosun Pharma Group is a listing enterprise which focuses its business in modern biomedical health industry. It has already gained the leading position in many segment markets, such as malaria, liver disease, diabetes, clinical diagnostic products while it is also the only supplier which has passed WHO-GMP and PQ certifications so far among pharmaceutical enterprises in China. Mr. Li Xianlin, the Senior Vice President of Fosun Pharma and the Chairman of Pharmaceutical Industry Management Committee, stated, “Hongqi Pharma is already the leading enterprise of antitubercular drugs industry in China.

Fosun Pharma will take advantage of our experiences and superiorities in funds, personnel, management, investment acquisitions, industry consolidation, etc, to support Hongqi Pharma to explore the global market of antitubercular drugs. In the future, Fosun Pharma will also, taking the existing anti-malarial medicine, tuberculosis and other platforms as bases, to actively create a platform for infectious disease drugs, and promote China's infectious drugs into the international market to benefit patients worldwide.”